The Oncology Institute, Inc.
TOI
$3.78
$0.020.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.70% | 21.53% | 10.29% | 16.88% | 21.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.70% | 21.53% | 10.29% | 16.88% | 21.78% |
| Cost of Revenue | 37.54% | 19.58% | 5.39% | 19.92% | 29.49% |
| Gross Profit | 31.70% | 34.35% | 44.11% | 1.79% | -10.09% |
| SG&A Expenses | -5.24% | -3.46% | -10.81% | -11.86% | -5.39% |
| Depreciation & Amortization | 9.54% | 18.91% | 19.81% | 8.24% | -7.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.13% | 13.98% | 1.49% | 10.88% | 18.59% |
| Operating Income | 41.86% | 31.49% | 44.85% | 22.54% | 0.22% |
| Income Before Tax | -2.43% | -10.73% | 1.53% | 30.87% | 6.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.43% | -9.88% | 1.53% | 29.71% | 7.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.43% | -9.88% | 1.53% | 29.71% | 7.50% |
| EBIT | 41.86% | 31.49% | 44.85% | 22.54% | 0.22% |
| EBITDA | 48.44% | 36.64% | 50.69% | 26.05% | -0.77% |
| EPS Basic | 19.30% | 11.50% | 4.88% | 31.23% | 9.84% |
| Normalized Basic EPS | 20.63% | 11.00% | 22.49% | 33.45% | 9.26% |
| EPS Diluted | 21.50% | 11.71% | 4.55% | 30.77% | 7.31% |
| Normalized Diluted EPS | 20.63% | 11.00% | 22.49% | 33.45% | 9.26% |
| Average Basic Shares Outstanding | 29.06% | 24.69% | 3.86% | 2.98% | 2.80% |
| Average Diluted Shares Outstanding | 29.06% | 24.69% | 3.86% | 2.98% | 2.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |